GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (STU:6IB) » Definitions » Price-to-Owner-Earnings

Innovent Biologics (STU:6IB) Price-to-Owner-Earnings : (As of May. 17, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Price-to-Owner-Earnings?

As of today (2024-05-17), Innovent Biologics's share price is €4.62. Innovent Biologics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Innovent Biologics's Price-to-Owner-Earnings or its related term are showing as below:


STU:6IB's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.045
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-17), Innovent Biologics's share price is €4.62. Innovent Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.09. Therefore, Innovent Biologics's PE Ratio for today is At Loss.

As of today (2024-05-17), Innovent Biologics's share price is €4.62. Innovent Biologics's EPS without NRI for the trailing twelve months (TTM) ended in was €-0.09. Therefore, Innovent Biologics's PE Ratio without NRI for today is At Loss.


Innovent Biologics Price-to-Owner-Earnings Historical Data

The historical data trend for Innovent Biologics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Price-to-Owner-Earnings Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Innovent Biologics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Innovent Biologics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovent Biologics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Price-to-Owner-Earnings falls into.



Innovent Biologics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Innovent Biologics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4.62/-0.09
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovent Biologics  (STU:6IB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Innovent Biologics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovent Biologics (STU:6IB) Business Description

Traded in Other Exchanges
Address
168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (STU:6IB) Headlines

No Headlines